Flow Neuroscience closes $12.7M Series B to fund US FDA pivotal trial for depression tDCS

Summary

Swedish tDCS company Flow Neuroscience secured $12.7M Series B from Abdon Lagesen Eriksson, LSP, and Industrifonden. The smaller round is focused specifically on funding the MINDFUL-1 US pivotal trial for treatment-resistant depression. CE mark already secured in 30 European countries. US clearance would unlock the largest depression device market globally.